Pasireotide
As of the edition of 20 October 2026, Pasireotide is a protein: marketed, first approved in 2012 (EU); acts on SSTR2, SSTR3 and SSTR5; US protection ends in 2026.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2016
- Kind
- Protein
- Brand name
- Signifor
- First approved
- 24 April 2012 (EU)
- Approvals on record
- 19 in 4 regions
- Holder of the most recent approval
- Recordati Rare Diseases; 2 holders in all
- Registered trials
- 72, 15 stopped early
- Disease areas
- Cancer; Hormones; Nervous system; Digestive system; Bones, joints and muscles; Nutrition and metabolism
US protection
US protection ends in 2026.
The last listed US drug-substance patent ends in 2026. The application that gives this date is held by Recordati Rare Diseases.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product8 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 8 listings behind itRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 2 | 0 | 0 |
| Phase 1 | 14 | 14 | 0 | 0 |
| Phase 2 | 40 | 22 | 3 | 14 |
| Phase 3 | 7 | 7 | 0 | 0 |
| Phase 4 | 7 | 4 | 0 | 1 |
| All trials | 72 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Recordati Rare Diseases | Applicant | 2012 to now |
| Novartis | Applicant and Lead sponsor of trials | 2012 to now |